Physician profile
Daniel C Cole
NPI 1821521220
$2,428.61
in general payments reported to CMS, 2019-2025
28 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $275 · 2023: $366 · 2024: $550 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785 · Education: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.64 |
| Education | $368.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $448.65 | 2023-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $266.36 | 2023-2025 | Reblozyl, Opdivo |
| Gilead Sciences, INC. | $239.69 | 2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $237.43 | 2024-2025 | |
| Daiichi Sankyo INC. | $185.61 | 2022-2025 | Enhertu |
| Seagen INC. | $150.00 | 2022 | |
| Genzyme Corporation | $143.87 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $99.21 | 2024-2025 | Keytruda, Welireg |
| Glaxosmithkline, LLC. | $76.13 | 2025 | Ojjaara, Blenrep |
| Ipsen Biopharmaceuticals, INC | $69.18 | 2025 | Onivyde |
| Incyte Corporation | $65.29 | 2025 | Jakafi, Zynyz, Monjuvi |
| Alexion Pharmaceuticals, INC. | $53.39 | 2024-2025 | Ultomiris |
| Celgene Corporation | $42.10 | 2025 | Reblozyl |
| Pfizer INC. | $37.12 | 2024 | |
| Lilly USA, LLC | $36.17 | 2025 | Verzenio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $33.12 | 2024 | Yescarta |
| Emd Serono, INC. | $29.01 | 2023 | |
| Puma Biotechnology, INC. | $28.86 | 2025 | |
| Beigene USA, INC. | $25.88 | 2024 | Brukinsa |
| Exelixis INC. | $24.65 | 2024 | Cabometyx |
| Janssen Biotech, INC. | $21.71 | 2025 | Erleada |
| Deciphera Pharmaceuticals INC. | $20.37 | 2024 | Qinlock |
| Array Biopharma INC | $20.34 | 2024 | Xalkori, Braftovi, Lorbrena |
| Menarini Silicon Biosystems, INC. | $19.66 | 2025 | |
| Aimmune Therapeutics, INC. | $17.80 | 2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $17.30 | 2024 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $13.51 | 2025 | Imfinzi |
| Iovance Biotherapeutics, INC. | $6.20 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.